Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Yonsei University

Status: Completed

Conditions: Hepatocellular Carcinoma

Treatments: Drug: Statin

Study type: Observational

Funder types: Other

Identifiers

NCT03490461

4-2017-0942

Details and patient eligibility

About

This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.

Enrollment: 350 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who received LT at the Severance Hospital from 2006 to 2016.

Exclusion criteria

• early postoperative mortality (defined as death within 2 months after LT without signs of tumor recurrence)
• patient with distant lymph node metastasis confirmed within 1 month after LT
• Patients younger than 20 years of age
• patients who had LT for cirrhosis without confirmed HCC

Trial design

350 participants in 2 patient groups

Statin group

Description:

Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation

Treatment:

Drug: Statin

Non-statin group

Description:

the administration of statins for less than 30 days after liver transplantation